Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 145

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 145
---
 introductory videoconference meeting between representatives of Aadi and WuXi Biologics on June 20, 2024, Aadi entered into a three-way mutual confidentiality agreement with WuXi Biologics and Hangzhou DAC, a developer of linker-payload technology used in WuXi Biologics’ ADC portfolio, on July 2, 2024.

On July 9, 2024, the Strategic Transaction Committee held a meeting to discuss strategic opportunities with Aadi’s management team. At the meeting,
the committee deliberated with Aadi’s management team regarding a refined strategy for evaluating ADC opportunities, including establishing criteria for validated targets, limited competition, next wave linker-payload platforms, and the ability
of the drug program to go to the clinic in 12-18 months. Following the meeting, Aadi’s management team evaluated over 20 ADC companies and 40 ADC assets against the designated criteria and prioritized ADC
portfolios from five companies, including Wuxi Biologics, for further due diligence analysis.

On July 12, 2024, Aadi received access to the dataroom
of WuXi Biologics and commenced due diligence.

On July 17, 2024, representatives of Aadi, WuXi Biologics and Hangzhou DAC met via videoconference to
discuss the CPT113 linker-payload platform developed by Hangzhou DAC as well as the MUC16 ADC asset.

On July 18, 2024, representatives of Aadi and
WuXi Biologics met via video conference to discuss a potential transaction and discussed a potential in-license of the PTK7-CPT113 asset on a stand-alone basis.

On July 23, 2024, the Strategic Transaction Committee held a meeting to discuss strategic opportunities with Aadi’s management team. At the meeting,
the committee deliberated with Aadi’s management team regarding the potential in-license of PTK7-CPT113 as a stand-alone asset and determined not to pursue that opportunity.

On July 25, 2024, representatives of Aadi communicated to representatives of WuXi Biologics that Aadi was not interested in licensing PTK7-CPT113 as a
stand-alone asset. However, following discussion with Aadi’s business development consultant, on August 1, 2024, representatives of Aadi contacted representatives of WuXi Biologics to explore the possibility of licensing a multi-asset ADC
portfolio to compensate for the preclinical stage of the assets. Based on the